ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Phase 1

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Bimatoprost 1% Formulation A
Drug: Bimatoprost 1% Formulation B

First Posted Date: 2016-07-28

Last Posted Date: 2016-10-26

Lead Sponsor: Allergan

Target Recruit Count: 11

Registration Number: NCT02848300

Locations: 🇺🇸
DermResearch, LLC, Austin, Texas, United States

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Phase 2

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Atogepant
Drug: Placebo-matching Atogepant

First Posted Date: 2016-07-28

Last Posted Date: 2018-12-06

Lead Sponsor: Allergan

Target Recruit Count: 834

Registration Number: NCT02848326

Locations: 🇺🇸
Central Texas Neurology Consultant, Round Rock, Texas, United States
🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸
iResearch Atlanta, LLC, Decatur, Georgia, United States

and more 70 locations

A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

Not Applicable

Completed

Conditions: Chin Retrusion

Interventions: Device: JUVÉDERM VOLUMA® XC

First Posted Date: 2016-07-14

Last Posted Date: 2020-07-23

Lead Sponsor: Allergan

Target Recruit Count: 221

Registration Number: NCT02833077

Locations: 🇺🇸
Skin Research Institute, Coral Gables, Florida, United States
🇺🇸
Baumann Cosmetic and Res. Institute, Miami Beach, Florida, United States
🇺🇸
SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetts, United States

and more 11 locations

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Phase 3

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Ubrogepant
Drug: Placebo-matching Ubrogepant

First Posted Date: 2016-07-11

Last Posted Date: 2019-01-03

Lead Sponsor: Allergan

Target Recruit Count: 1672

Registration Number: NCT02828020

Locations: 🇺🇸
Prime Care Clinical Research, Laguna Hills, California, United States
🇺🇸
Medical Center for Clinical Research, San Diego, California, United States
🇺🇸
Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango, Las Vegas, Nevada, United States

and more 84 locations

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Phase 3

Terminated

Conditions: Dry Eye Syndromes

Interventions: Drug: Vehicle
Drug: AGN-195263

First Posted Date: 2016-06-28

Last Posted Date: 2019-02-19

Lead Sponsor: Allergan

Target Recruit Count: 36

Registration Number: NCT02815293

Locations: 🇺🇸
Eye Doctors of Washington, Chevy Chase, Maryland, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Eye Care Centers Management, Inc. dba Clayton Eye Center, Morrow, Georgia, United States

and more 26 locations

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Phase 2

Completed

Conditions: Alopecia

Interventions: Drug: Placebo
Drug: Setipiprant
Drug: Finasteride

First Posted Date: 2016-05-24

Last Posted Date: 2019-04-05

Lead Sponsor: Allergan

Target Recruit Count: 169

Registration Number: NCT02781311

Locations: 🇺🇸
DeNova Research, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States
🇺🇸
Heartland Research Associates, LLC, Wichita, Kansas, United States

and more 14 locations

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: AGN-199201 Vehicle
Drug: AGN-199201 ophthalmic solution
Drug: AGN-190584 ophthalmic solution
Drug: AGN-190584 Vehicle

First Posted Date: 2016-05-23

Last Posted Date: 2020-12-22

Lead Sponsor: Allergan

Target Recruit Count: 151

Registration Number: NCT02780115

Locations: 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸
Wolstan and Golberg Eye Associates, Torrance, California, United States
🇺🇸
MedEye Associates, Miami, Florida, United States

and more 22 locations

Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Completed

Conditions: Diabetic Macular Oedema

Interventions: Drug: dexamethasone intravitreal implant

First Posted Date: 2016-04-08

Last Posted Date: 2019-01-23

Lead Sponsor: Allergan

Target Recruit Count: 202

Registration Number: NCT02731911

Locations: 🇦🇺
Retina and Macula Specialists,Hurstville, Hurtsville, New South Wales, Australia
🇦🇺
Retina Associates, Liverpool, New South Wales, Australia
🇦🇺
Retina and Macula Specialists, Miranda, Miranda, New South Wales, Australia

and more 20 locations

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Phase 1

Terminated

Conditions: Alopecia, Androgenetic
Alopecia
Baldness

Interventions: Drug: Bimatoprost

First Posted Date: 2016-02-08

Last Posted Date: 2017-03-17

Lead Sponsor: Allergan

Target Recruit Count: 53

Registration Number: NCT02676310

Locations: 🇺🇸
J&S Studies Inc., College Station, Texas, United States
🇺🇸
E&R Research Foundation, Lynchburg, Virginia, United States
🇺🇸
DermResearch, LLC, Austin, Texas, United States

Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder

Completed

Conditions: Urinary Bladder, Overactive
Urinary Bladder, Neurogenic

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2016-02-03

Last Posted Date: 2016-10-24

Lead Sponsor: Allergan

Target Recruit Count: 474

Registration Number: NCT02673047

Locations: 🇫🇷
CH Bagnols Sur Ceze, Bagnols-Sur-Ceze, France
🇫🇷
CL Toulouse Lautrec, Albi, France
🇫🇷
CH Angouleme, Angouleme Cedex 9, France

and more 47 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy